Skip to main content

Table 2 Perioperative Fibrinogen, D-Dimers and TEG test at different time points between the three groups

From: Comparison of the in-vivo effect of two tranexamic acid doses on fibrinolysis parameters in adults undergoing valvular cardiac surgery with cardiopulmonary bypass - a pilot investigation

 

Placebo group (n = 10)

Low dose group (n = 10)

High dose group (n = 10)

P-value

Fibrinogen [mean (SD); g/L]

 Preoperative

3.2 ± 0.9

3.0 ± 0.4

3.5 ± 1.1

0.408

 Intra-operative period

   

0.786

  T1

3.1 ± 0.8

3.1 ± 0.4

3.4 ± 0.8

 

  T2

3.0 ± 0.9

2.9 ± 0.4

3.2 ± 0.8

 

  T3

1.43 ± 0.30

1.55 ± 0.25

1.50 ± 0.35

 

  T4

1.7 ± 0.4

1.8 ± 0.4

1.7 ± 0.5

 

  T5

1.7 ± 0.5

1.9 ± 0.4

1.8 ± 0.5

 

when arriving at ICU

2.0 ± 0.5

2.1 ± 0.4

2.1 ± 0.5

0.875

In the first post-operative morning

2.9 ± 1.1

3.1 ± 1.2

4.3 ± 0.8b

0.027

D-Dimer [median (IQR); ug/L]

 Preoperative

290 (213–705)

235 (188–518)

280 (210–665)

0.715

 Intra-operative period

   

0.465

  T1

305 (255–470)

305 (228–445)

295 (220–500)

 

  T2

330 (270–490)

315 (270–443)

295 (220–545)

 

  T3

305 (248–370)

220 (220–270)

235 (220–308)

 

750 (415–1133)

420 (318–555)

280 (220–393)

 

  T5

745 (430–1343)

480 (235–605)

255 (220–373)

 

when arriving at ICU

1540 (1078–1900)

555 (483–770)a

260 (220–440)b

< 0.001

In the first post-operative morning

1530 (1030–2155)

710 (520–1070)a

540 (405–880)b

0.008

TEG-R [mean (SD); min]

   

0.439

 T1

6.8 ± 1.7

5.9 ± 1.1

5.7 ± 1.0

 

 T2

6.3 ± 1.9

6.4 ± 1.4

5.5 ± 0.8

 

 T5

5.9 ± 1.5

7.9 ± 2.7

6.7 ± 3.2

 

TEG-K [median (IQR); min]

   

0.551

 T1

1.75 (1.68–2.50)

1.60 (1.40–1.85)

1.35 (1.15–1.63)

 

 T2

2.00 (1.30–2.45)

1.85 (1.55–1.93)

1.65 (1.20–2.05)

 

 T5

2.40 (1.85–3.05)

2.30 (2.00–3.10)

2.60 (1.85–3.20)

 

TEG-Angle [mean (SD); °]

   

0.420

 T1

68.8 ± 7.0

72.1 ± 3.3

74.3 ± 2.3

 

 T2

70 ± 5

68 ± 9

73 ± 4

 

 T5

68 ± 5

65 ± 8

66 ± 7

 

TEG-MA [mean (SD); mm]

   

0.618

 T1

63 ± 6

64 ± 3

66 ± 4

 

 T2

62 ± 5

63 ± 4

66 ± 4

 

 T5

52 ± 6

52 ± 5

51 ± 9

 

TEG-EPL [median (IQR); %]

   

0.779

 T1

0.20 (0–0.90)

0 (0–0.18)

0 (0–0.38)

 

 T2

0 (0–0.20)

0 (0–0.03)

0 (0–0.10)

 

 T5

0 (0–0.80)

0 (0–0.45)

0 (0–0.85)

 

TEG-A [mean (SD); mm]

   

0.600

 T1

62 ± 6

63 ± 4

65 ± 6

 

 T2

62 ± 5

62 ± 5

65 ± 6

 

 T5

50 ± 6

51 ± 7

51 ± 10

 

TEG-LY30[median (IQR); %]

   

0.427

 T1

0 (0–0.25)

0 (0–0.13)

0 (0–0.23)

 

 T2

0 (0–0.05)

0 (0–0.03)

0 (0–0.10)

 

 T5

0 (0–0.8)

0 (0–0.45)

0 (0–0.85)

 

TEG-CI [median (IQR)]

   

0.433

 T1

0.8(−1.2–1.2)

1.0 (0.5–1.7)

1.8 (1.3–2.6)

 

 T2

−0.2[(−1.0)-2.2]

0.9[(−0.6)-1.7]

1.4 (0.6–2.4)

 

 T5

−0.9[(−2.5)-(−0.2)]

−2.1[(−5.2)-(−0.4)]

−1.5[(−2.9)-0.7]

 
  1. a: Low-dose group compared with placebo group; b: High-dose group compared with placebo group. T1 = per-operatively before TXA injection (baseline); T2 = 5 min after TXA bolus administration (bolus); T3 = 5 min after the onset of CPB (CPB); T4 = 5 min before the end of CPB (End of CPB); T5 = 5 min after protamine injection (protamine)
  2. T1 = per-operatively before TXA injection (baseline); T2 = 5 min after TXA bolus administration (bolus); T3 = 5 min after the onset of CPB (CPB); T4 = 5 min before the end of CPB (End of CPB); T5 = 5 min after protamine injection (protamine). R Reaction time, MA Maximum amplitude, A Amplitude of clot firmness after clotting time, CI Coagulation index
Back to article page

BMC Anesthesiology

ISSN: 1471-2253

Contact us